Helius Medical Technologies Secures Reimbursement Milestone for Revolutionary MS Treatment Device, Extends Financial Stability Until 2024
In a significant development for the healthcare industry, Helius Medical Technologies, Inc. has successfully obtained HCPCS codes for their groundbreaking Portable Neuromodulation Stimulator (PoNS) Mouthpiece and Controller. This achievement marks a major step toward reimbursement for the only medical device approved in the U.S. for the treatment of gait deficit resulting from multiple sclerosis (MS).
The PoNS device, manufactured by Helius Medical Technologies, Inc. combines neuromodulation and physical therapy to address the debilitating gait issues faced by MS patients. This non-invasive treatment has shown promising results in restoring balance and mobility, offering hope for individuals living with the challenges posed by MS.
The recent acquisition of HCPCS codes paves the way for reimbursement by insurance companies, which will significantly enhance access to this innovative treatment for MS patients. With insurance coverage, the financial burden will be alleviated for those individuals seeking the PoNS treatment, making it more accessible and affordable.
Furthermore, Helius Medical Technologies, Inc. has demonstrated financial stability and future growth potential through their recent stock issuances via the Company’s At-The-Market (ATM) program. The proceeds from these stock issuances have extended the company’s cash runway, ensuring financial sustainability until the third quarter of 2024.
This financial achievement reflects the confidence and faith investors have in Helius Medical Technologies, Inc. and their groundbreaking PoNS device. By securing long-term financial stability, the company can focus on expanding their reach and providing crucial support to a larger number of MS patients in need.
Helius Medical Technologies, Inc. has also showcased impressive revenue growth, with a year-on-year increase of 79.82%. This significant rise in revenue highlights the increasing demand for the PoNS device and the positive impact it has made on the lives of MS patients.
It is particularly noteworthy that not only has Helius Medical Technologies, Inc. experienced a surge in revenue, but their corporate clients have also benefited from the implementation of the PoNS device. The device has proven to be a valuable tool for healthcare providers, assisting them in enhancing patient outcomes and delivering superior care.
With the recent reimbursement milestone and financial stability, Helius Medical Technologies, Inc. is poised to continue making a significant impact in the lives of MS patients. The availability of insurance coverage for the PoNS device will ensure that individuals receive the vital treatment they need, improving their quality of life and enabling them to regain their mobility.
In summary, the attainment of HCPCS codes for the PoNS Mouthpiece and Controller heralds a major breakthrough in the field of MS treatment. Helius Medical Technologies, Inc.’s commitment to improving the lives of MS patients is showcased through their financial stability, diligent efforts to secure reimbursement, and impressive revenue growth. The future looks bright for both the company and those seeking relief from the burdensome symptoms of MS.
Comments